Last reviewed · How we verify
Dynastat (original Parecoxib)
Parecoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and provide anti-inflammatory and analgesic effects.
Parecoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and provide anti-inflammatory and analgesic effects. Used for Acute postoperative pain, Perioperative pain management.
At a glance
| Generic name | Dynastat (original Parecoxib) |
|---|---|
| Sponsor | University of Malaya |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
As a selective COX-2 inhibitor, parecoxib blocks the enzyme responsible for producing inflammatory prostaglandins while sparing COX-1, which protects the gastrointestinal tract. This selective inhibition provides pain relief and reduces inflammation with a lower risk of GI side effects compared to non-selective NSAIDs. Parecoxib is the intravenous prodrug form of valdecoxib.
Approved indications
- Acute postoperative pain
- Perioperative pain management
Common side effects
- Hypertension
- Cardiovascular events
- Nausea
- Headache
Key clinical trials
- Study Comparing Dynastat and Parestat Pain Relief Medications for Patients After Breast Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dynastat (original Parecoxib) CI brief — competitive landscape report
- Dynastat (original Parecoxib) updates RSS · CI watch RSS
- University of Malaya portfolio CI